Abstract
Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Current Drug Safety
Title:Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Volume: 8 Issue: 1
Author(s): Antonio Siniscalchi, Luca Gallelli, Simona Loizzo, Avenoso Tiziana, Emilio Russo and Giovambattista De Sarro
Affiliation:
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Abstract: Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Export Options
About this article
Cite this article as:
Siniscalchi Antonio, Gallelli Luca, Loizzo Simona, Tiziana Avenoso, Russo Emilio and Sarro Giovambattista De, Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome, Current Drug Safety 2013; 8 (1) . https://dx.doi.org/10.2174/1574886311308010010
DOI https://dx.doi.org/10.2174/1574886311308010010 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design A Review on Pharmacokinetics of Levetiracetam in Neonates
Current Drug Metabolism Drug Trials in Dementia: Challenging Ethical Dilemmas
Current Alzheimer Research Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry Functional Connectivity in a Rat Model of Alzheimer's Disease During a Working Memory Task
Current Alzheimer Research Past, Present and Future of Antiepileptic Drug Therapy - Finding a Place for Heterocyclics
Mini-Reviews in Medicinal Chemistry Persons with Co-Existing Neurological Disorders: Risk Analysis, Considerations and Management in COVID-19 Pandemic
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms of Cardiac Voltage-Gated Potassium Channelopathies
Current Pharmaceutical Design ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry Homocysteine and Folate Therapy in Dialysis Patients
Letters in Drug Design & Discovery Increased Neuronal Injury in Clock Gene Per-1 Deficient-Mice after Cerebral Ischemia
Current Neurovascular Research Manipulation of Intracellular pH in Cancer Cells by NHE1 Inhibitors
Protein & Peptide Letters Editorial: Zebrafish Psychopharmacology
Current Psychopharmacology Piperine from Black Pepper Decreased the Expression of Intercellular Adhesion Molecule-1 in Macrophages
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Safety of Medications for the Treatment of Bipolar Disorder During Pregnancy and the Puerperium
Current Drug Safety A Rapid, Green, Efficient Microwave-Assisted Synthesis and Antimicrobial Activity of Novel Glycinamide of 6,7-Dimethoxy-1, 2, 3, 4-Tetrahydroisoquinolines
Current Microwave Chemistry Synthesis and Evaluation of Schiff Bases for Anticonvulsant and Behavioral Depressant Properties
Central Nervous System Agents in Medicinal Chemistry Targeting Neuronal Nicotinic Receptors: a Path to New Therapies
Current Drug Targets - CNS & Neurological Disorders Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses AMPK As A Target in Rare Diseases
Current Drug Targets